BridgeMD
Compares treatment options for Psoriasis Vulgaris
Official title Proactive TDM Versus Standard Use of Biologics in Psoriasis
ClinicalTrials.gov ID: NCT06398106
What this study is testing
What is Proactive TDM-based dosing of secukinumab?
Proactive TDM-based dosing of secukinumab is an investigational medicine, given as an once-daily injectable medicine, being studied as a potential treatment for psoriasis vulgaris.
Also referred to as Cosentyx.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Biologics are effective agents for the treatment of psoriasis. The newest generation of biologics block interleukin 17 and 23.
- Phase 4: studies an already-approved treatment
- Time commitment: about 18 months
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults; aged 18 years or older
- Documented diagnosis of psoriasis (predominantly type vulgaris; based on clinical diagnosis) by an accredited dermatologist
- Patients must be currently treated with secukinumab, ixekizumab or guselkumab ≥ 6 months according to the standard dosing scheme.
- The subject signs and dates a written informed consent form and any required privacy authorization prior to the initiation of any study procedures
You likely can't join if
- Another indication than plaque psoriasis as the main indication for biologic use (e.g. receives biologic for rheumatoid arthritis as the main...
- Concomitant use of systemic immunosuppressants other than methotrexate or acitretin (e.g. prednisone, cyclosporine etc)
- Severe comorbidities with short life-expectancy (e.g. metastasized tumour) or uncontrolled PsA at inclusion/baseline
- Presumed inability to follow the study protocol
- Active pregnancy wish
The study team makes the final eligibility decision.
Where it's taking place
- Bruges, Belgium
- Brussels, Belgium
- Charleroi, Belgium
- Eeklo, Belgium
- Geel, Belgium
- Ghent, Belgium
- Herstal, Belgium
- Kortrijk, Belgium
- Leuven, Belgium
- Liège, Belgium
- Maldegem, Belgium
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 18 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bruges, Belgium; Brussels, Belgium; Charleroi, Belgium; Eeklo, Belgium; Geel, Belgium; Ghent, Belgium and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.